Key Takeaway From 2-Year Follow-Up Data of ZUMA-1 Trial in Large B-Cell Lymphoma

Video

Sattva S. Neelapu, MD, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.

Sattva S. Neelapu, MD, a professor in lymphoma and myeloma at MD Anderson Cancer Center, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B-cell lymphoma.

After a median follow-up of 27 months, overall survival (OS) has not been reached. According to Neelapu, this is an almost 4 month increase compared to historical data for traditional therapies where OS is expected to be around 6 months.

Related Videos
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content